BioInvent's BI-1808 and KEYTRUDA(R) Induce Durable Responses in Heavily ...
(PR-inside.com) BioInvent International (STO:BINV) - Updated efficacy data in 34 evaluable patients with a chemotherapy-free regimen; randomized Part C will add BI-1808 to the new standard of care 24% objective response rate (8 of 34 evaluable patients: 1 complete and 7 partial responses), including patients with high-…
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


